HARBOUR BIOMED

和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

RESIGNATION OF EXECUTIVE DIRECTOR; APPOINTMENT OF EXECUTIVE DIRECTORS; AND CHANGE OF AUTHORIZED REPRESENTATIVE

The board (the "**Board**") of directors (the "**Directors**" and each a "**Director**") of HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces the following changes.

RESIGNATION OF EXECUTIVE DIRECTOR

Dr. Yiping Rong ("**Dr. Rong**") has tendered his resignation as an executive Director with effect from 27 August 2026 (the "**Effective Date**") due to personal reasons.

Dr. Rong has confirmed that he has no disagreement with the Board and that there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its sincere gratitude to Dr. Rong for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTORS

The Board is pleased to announce that, after taking into consideration the recommendation from the nomination committee of the Board (the "**Nomination Committee**"), with effect from the Effective Date, Mr. Youchen Chen (陳侑晨) ("**Mr. Chen**") and Dr. Ian Yi Liu (劉毅) ("**Dr. Liu**") have been appointed as executive Directors. Their biographical details are set out below.

Mr. Youchen Chen

Mr. Youchen Chen (陳侑晨), aged 37, joined the Group in October 2023 as Vice President of Finance, Corporate Development and Capital Markets and served in such capacity until April 2025. He has been serving as the Chief Financial Officer of the Company since April 2025 and is responsible for the Group's global financial strategy, financial operations, investor relation, corporate development (APAC) and strategic investment activities.

Mr. Chen has over 15 years of experience in finance and accounting, investment banking, corporate finance and capital markets, with particular expertise in financial management, transaction execution, corporate finance and investor relations. Prior to joining the Group, Mr. Chen worked in the Investment Banking and Capital Market (IBCM) division at Credit Suisse Securities (China) Limited as a vice president from June 2021 to March 2023, covering Greater China healthcare, life science and tech sectors as a coverage officer. From June 2020 to April 2021, Mr. Chen served as head of corporate finance of Yidu Tech Inc. (2158.HK). From July 2017 to June 2020, he worked in the investment banking division of Credit Suisse Securities (China) Limited as senior associate. He also served in the audit department of KPMG Huazhen LLP, Shanghai Branch from October 2011 to April 2014, with his last position as an assistant manager.

Mr. Chen obtained a Bachelor of Laws degree from Fudan University in the PRC in July 2011. He further obtained a Master of Business Administration (MBA) degree from the McDonough School of Business at Georgetown University in the United States in May 2017. Mr. Chen was granted the Hong Kong Securities Industry Practitioner Qualification recognized by the Securities and Futures Commission of Hong Kong and also holds securities practitioner qualifications in the PRC.

As at the date of this announcement, Mr. Chen holds 74,500 shares, 812,500 restricted share units and options over 2,780,000 shares of the Company granted pursuant to the Company's share incentive schemes.

Dr. Ian Yi Liu

Dr. Ian Yi Liu, Ph.D., J.D. (劉毅), aged 55, joined the Company in March 2025 as Senior Vice President and Global Head of Legal, and has been serving as a joint company secretary of the Company since 9 June 2025. Dr. Liu is responsible for assisting the Board on making strategic directions and overseeing the Group's global legal, corporate governance and risk management matters, including business development and licensing transactions, intellectual property strategy and protection, and other legal and compliance matters.

Prior to joining the Group, Dr. Liu served as head of legal and government affairs and head of operations of Simcere of America, Inc., a member of Simcere Pharmaceutical Group Limited (2096.HK), from March 2021 to March 2025. From April 2017 to March 2021, he served as general legal counsel and company secretary of Breas Medical Holdings AB, a member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK; 600196.SH). Dr. Liu previously served as executive director of legal affairs and corporate administration of Boston Biomedical, Inc., from February 2015 to April 2017 and as senior counsel of Idenix Pharmaceuticals, Inc., from February 2014 to December 2014. He also practiced law at Finnegan, Henderson, Farabow, Garrett & Dunner LLP from November 2008 to February 2014 and at K&L Gates LLP from November 2006 to October 2008.

Dr. Liu became a member of the Bar in the Commonwealth of Massachusetts, USA, in 2006. He is admitted to practice before the Supreme Judicial Court of the Commonwealth of Massachusetts, the United States District Court for the District of Massachusetts, the United States Court of Appeals for Veterans Claims and the United States Patent and Trademark Office. Dr. Liu is also a notary public appointed by the Governor of the Commonwealth of Massachusetts, USA.

Dr. Liu obtained a Bachelor of Science degree in Chemistry from Fudan University in PRC in May 1993, a Ph.D. degree in Chemistry from Worcester Polytechnic Institute in the United States in May 2002, and a Juris Doctor degree from Suffolk University Law School in the United States in May 2006.

As at the date of this announcement, Dr. Liu holds 701,000 restricted share units and options over 1,440,000 shares of the Company granted pursuant to the Company's share incentive schemes.

Each of Mr. Chen and Dr. Liu has entered into a service contract with the Company for an initial term of three (3) years commencing on the Effective Date and until terminated by either party by giving not less than three months' notice. However, each of Mr. Chen and Dr. Liu will hold office only until the next annual general meeting of the Company after his appointment, and will be subject to retirement by rotation and re-election at the next annual general meeting of the Company in accordance with the memorandum and articles of association of the Company (the "**Articles**"). Mr. Chen's and Dr. Liu's monthly emolument for their respective roles in the Group is HKD179,725.00 and US$34,168.75, respectively, and discretionary bonus shall be determined based on their annual performance assessment, which was determined by the Board with recommendation of the remuneration committee of the Board after taking into account their respective duties and responsibilities within the Company and prevailing market conditions. Each of Mr. Chen and Dr. Liu is not entitled to receive any director's fee for his role as an executive Director.

Save as disclosed in this announcement, as at the date of this announcement, each of Mr. Chen and Dr. Liu has confirmed that he (i) does not have any other interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company and other members of the Group; (iii) does not have any relationship with any other Directors, senior management, substantial Shareholders, or controlling Shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company; and (iv) does not hold any directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed in this announcement, to the best knowledge, information and belief of the Directors having made all reasonable enquiries, there is no other information relating to the appointment of Mr. Chen and Dr. Liu that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there is no other matter in relation to their appointment that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board wishes to take this opportunity to extend its warmest welcome to Mr. Chen and Dr. Liu on their new appointments.

CHANGE OF AUTHORIZED REPRESENTATIVE

Following the resignation of Dr. Rong, he has also ceased to act as an authorized representative of the Company (an "**Authorized Representative**") under Rule 3.05 of the Listing Rules. The Board announces that Mr. Youchen Chen (陳侑晨) has been appointed as an Authorized Representative with effect from the Effective Date to fill the vacancy following Dr. Rong's cessation to act in the same capacity as mentioned above.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 27 August 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.